Accrued expenses and other current liabilities (Tables)

6 Months Ended

Jun. 30, 2024

Payables and Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of June 30, 2024		As of December 31, 2023
Collaboration research costs	$	12,107	$	5,681
Employee compensation, including severance for restructuring	6,588		4,639
Royalties	3,469		9,702
Clinical and contract research organization costs	883		990
Manufacturing costs	525		1,764
Property, plant, and equipment	17		279
Deferred transition services income (1)	888		—
Other	4,225		2,633
Total accrued expenses and other current liabilities	$	28,702	$	25,688

(1) Refer to Note 3, Asset Purchase Agreements, for further information regarding deferred transition services income relating to the Novo Transaction.